Patents Assigned to Neuracle Science Co., Ltd.
-
Publication number: 20250067755Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.Type: ApplicationFiled: July 18, 2024Publication date: February 27, 2025Applicant: Neuracle Science Co., Ltd.Inventors: Jae Young SEONG, Byung Joo HAM, Min-Hyeok LEE, Nui HA
-
Patent number: 12215338Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.Type: GrantFiled: May 8, 2019Date of Patent: February 4, 2025Assignees: Neuracle Science Co., Ltd., Neuracle GeneticsInventors: Jong-Mook Kim, Dong Sik Kim, Juwon Shim, Soon-gu Kwon
-
Publication number: 20240360209Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.Type: ApplicationFiled: April 1, 2024Publication date: October 31, 2024Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Wonkyum KIM, Jeongwon YOON, Junho CHUNG, Junyeong JIN, Eunhwoi YOU
-
Patent number: 12077579Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.Type: GrantFiled: September 14, 2021Date of Patent: September 3, 2024Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
-
Patent number: 12072339Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.Type: GrantFiled: October 2, 2018Date of Patent: August 27, 2024Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Byung Joo Ham, Min-Hyeok Lee, Nui Ha
-
Publication number: 20240182555Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.Type: ApplicationFiled: July 27, 2023Publication date: June 6, 2024Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
-
Publication number: 20240166735Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: July 11, 2023Publication date: May 23, 2024Applicant: Neuracle Science Co., Ltd.Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
-
Patent number: 11970532Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: May 10, 2019Date of Patent: April 30, 2024Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
-
Publication number: 20230357378Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.Type: ApplicationFiled: April 17, 2023Publication date: November 9, 2023Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
-
Publication number: 20230348584Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.Type: ApplicationFiled: January 23, 2023Publication date: November 2, 2023Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Eun Bee CHO, Dong Sik KIM, Jae-Keun LEE, Soon-gu KWON, Jae Young SEONG, Juwon SHIM, Tae Woo KIM, Shin-hyuk KANG
-
Publication number: 20230287096Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.Type: ApplicationFiled: March 2, 2023Publication date: September 14, 2023Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Jae-Keun LEE, Dong Sik KIM, Junho CHUNG, Junyeong JIN
-
Patent number: 11746149Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.Type: GrantFiled: June 27, 2018Date of Patent: September 5, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Dong Sik Kim, Soon-gu Kwon
-
Patent number: 11739141Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: March 3, 2020Date of Patent: August 29, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Patent number: 11634484Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.Type: GrantFiled: April 24, 2019Date of Patent: April 25, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Dong Sik Kim, Soon-Gu Kwon
-
Patent number: 11618783Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.Type: GrantFiled: June 27, 2018Date of Patent: April 4, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim, Junho Chung, Junyeong Jin
-
Patent number: 11560425Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.Type: GrantFiled: June 27, 2018Date of Patent: January 24, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Eun Bee Cho, Dong Sik Kim, Jae-Keun Lee, Soon-gu Kwon, Jae Young Seong, Juwon Shim, Tae Woo Kim, Shin-hyuk Kang
-
Patent number: 11332521Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: November 7, 2017Date of Patent: May 17, 2022Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
-
Publication number: 20220073601Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.Type: ApplicationFiled: September 14, 2021Publication date: March 10, 2022Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Jae-Keun LEE, Dong Sik KIM
-
Patent number: 11248023Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: GrantFiled: July 15, 2019Date of Patent: February 15, 2022Assignee: Neuracle Science Co., LtdInventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
-
Publication number: 20210388382Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.Type: ApplicationFiled: May 8, 2019Publication date: December 16, 2021Applicants: Neuracle Science Co., Ltd., Neuracle GeneticsInventors: Jong-Mook KIM, Dong Sik KIM, Juwon SHIM, Soon-gu KWON